Your Team for Swiss Law – now also in Geneva

3 October 2019

Versantis, a clinical-stage biotech company developing disruptive therapies for rare liver and pediatric diseases, completed an oversubscribed CHF 16 million Series B financing round. Swisscanto Invest by Zürcher Kantonalbank led the financing and was joined by Esperante Ventures and investiere, as well as new private investors. Existing investors Redalpine HealthEquity, and Zürcher Kantonalbank Start-up Finance also participated in this round. Earlier in the year, Versantis started a first-in-human clinical trial with VS-01, a multi-organ supporting therapy for liver cirrhosis. The proceeds from this new financing will be mainly used to assess the safety of VS-01 after multiple doses and establish its clinical proof of concept in the decompensated liver cirrhosis indication as well as in the rare Acute-on-Chronic Liver Failure (ACLF) patient population. VISCHER AG advised Versantis; the team was led by Matthias Staehelin with Sebastian Flückiger and Francesca Pesenti (all Corporate).

Press release Versantis

Categories: Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk

You are currently offline. Some pages or content may fail to load.